Patient's Derived Organoids for Drug Screening in Glioblastoma

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorFondazione Policlinico Universitario Agostino Gemelli IRCCS

About this trial

The study will enroll patients suffering from glioblastoma, a malignant brain tumor. Intervention is intended as a laboratory intervention and not as a clinical intervention. In fact, tumor removed from patients' brains will be sent to a dedicated laboratory to obtain an "avatar" of the tumor, named patient-derived organoid (PDO). A number of experimental antitumor approaches will be studied on PDOs. Results of these experiments will be correlated to the prognosis of patients.

Eligibility criteria

Qualifiers

adult patients undergoing resective neurosurgery for glioblastoma, IDH-wildtype

Disqualifiers

Needle biopsies

Age <18 years

Inability to give informed consent

Brain surgery for tumor disease other than GBM

Trial design

Treatments tested in this trial

  • Development and characterization of PDOs
  • Evaluation of the effects of epigenetic and splicing inhibitors on viability and gene expression signatures of GBM PDOs and GSCs

Treatment groups

100 Participants
are divided into 1 treatment group